{"id":"iv-furosemide-and-po-metolazone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Ototoxicity (with high-dose IV furosemide)"},{"rate":null,"effect":"Dehydration"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL35","moleculeType":"Small molecule","molecularWeight":"330.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, while metolazone is a thiazide-like diuretic that blocks the Na-Cl cotransporter in the distal convoluted tubule. Combined use produces a sequential nephron blockade effect, enhancing diuresis in patients with severe fluid retention or diuretic resistance.","oneSentence":"IV furosemide and PO metolazone work synergistically as loop and thiazide-like diuretics to increase sodium and water excretion, reducing fluid overload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:35.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Edema and fluid overload in heart failure"},{"name":"Diuretic-resistant edema in renal or hepatic disease"}]},"trialDetails":[{"nctId":"NCT06414759","phase":"PHASE4","title":"Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Acute Decompensated Heart Failure, Volume Overload, Edema","enrollment":110},{"nctId":"NCT05904808","phase":"PHASE4","title":"The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2023-04-19","conditions":"Chronic Heart Failure, Diuretics Drug Reactions, Congestive Heart Failure","enrollment":42},{"nctId":"NCT04572867","phase":"NA","title":"Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure","status":"WITHDRAWN","sponsor":"Ramona Gelzer Bell","startDate":"2021-06-08","conditions":"Heart Failure, Congestive Heart Failure, Decompensated Heart Failure","enrollment":""},{"nctId":"NCT00904488","phase":"PHASE4","title":"Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-10","conditions":"Acute Decompensated Heart Failure","enrollment":11},{"nctId":"NCT01921829","phase":"PHASE4","title":"Protocolized Diuretic Strategy in Cardiorenal Failure","status":"TERMINATED","sponsor":"Kelly V. Liang, MD","startDate":"2013-11","conditions":"Cardiac Failure, Renal Failure, Kidney Failure","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IV Furosemide and PO Metolazone","genericName":"IV Furosemide and PO Metolazone","companyName":"Rambam Health Care Campus","companyId":"rambam-health-care-campus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IV furosemide and PO metolazone work synergistically as loop and thiazide-like diuretics to increase sodium and water excretion, reducing fluid overload. Used for Edema and fluid overload in heart failure, Diuretic-resistant edema in renal or hepatic disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}